Biological/Vaccine

Phase 3Vaccine

Vertex Pharmaceuticals

Biological/Vaccine is one of 86 biologic programs targeting Endometriosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndometriosisActive, not recruiting

Gastrointestinal CancerNot yet recruiting

Kidney TransplantRecruiting

EndometriosisPreclinical

Active, not recruiting

Gastrointestinal CancerPhase 1

Not yet recruiting

Kidney TransplantPhase 3

Recruiting

Competition

Competitive Landscape

121 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

3 2

Felzartamab

Biogen

Phase 3

1 3

Envarsus XR

UUniversity of Wisconsin, Madison

Phase 3

2 4

Biological/Vaccine

Vertex Pharmaceuticals

Phase 3

1 5

Cytogam

JJohns Hopkins University

Phase 3

2 6

Zemplar

AbbVie

Preclinical

2 7

Radicava

Shionogi

Preclinical

1 8

Cysteine Hydrochloride

Novartis

Preclinical

1 9

Sensipar

Amgen

Preclinical

1 10

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Kidney Transplant

NCT06832410

Q3 2028

Phase 1Not yet recruiting

Gastrointestinal Cancer

NCT07735065

Q4 2040

Recruiting

Endometriosis

NCT04481321

Clinical

Trials by Indication[1]

Endometriosis1 trial

Clinical and Molecular Study of Endometriosis and Adenomyosis

Recruiting·AAssistance Publique - Hôpitaux de Paris··NCT04481321·5,300 enrolled

Acute Lymphoblastic Leukemia1 trial

Human Safety of Capsaicin Inhalation Challenge Testing for Young and Older Men

Completed·UUniversity of South Florida·Phase 1·NCT01621685·40 enrolled

Kidney Transplant1 trial

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

Recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 3·NCT06832410·10 enrolled

Gastrointestinal Cancer1 trial

A Single-Arm, Interventional, Exploratory Clinical Study of Tumor-Specific Cytotoxic T-Cell Injection (cCTL:GL01) for the Treatment of Advanced Gastrointestinal Tumors

Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1·NCT07735065·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Biological/Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biological/Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biological/Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vertex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: Vertex Pharmaceuticals

Biological/Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Q4 2040

Trials by Indication[1]

Endometriosis1 trial

Acute Lymphoblastic Leukemia1 trial

Kidney Transplant1 trial

Gastrointestinal Cancer1 trial

References

Drug Info

Quick Facts

Related News